跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
NAT-ABIRATERONE
Authorized
STANDARD
NAT-ABIRATERONE
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f2d1bdc84d18ef50
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
f2d1bdc84d18ef50
Drug Approval Canada Name
NAT-ABIRATERONE
Product Name
NAT-ABIRATERONE
Status
Marketed
Status Date
2021-01-18
Original Market Date
2021-01-18
Din
02494132
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L02BX03 ABIRATERONE
Atc Name
l 02 bx 03
Aig Number
0152948001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
ABIRATERONE ACETATE
250 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f2d1bdc84d18ef50
Type
Standard
Back to Health Canada Approvals
NAT-ABIRATERONE - Health Canada Drug Approval Details